Navigation Links
Abaxis Reports Financial Performance with Record Sales for the Second Quarter of Fiscal 2011
Date:10/26/2010

UNION CITY, Calif., Oct. 26 /PRNewswire-FirstCall/ -- ABAXIS, Inc. (Nasdaq: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today reported financial results for the fiscal quarter ended September 30, 2010.

Record quarterly highlights include:

  • Revenues of $35.3 million, up 17% over last year's comparable quarter.
  • North America revenues of $29.5 million, up 19% over last year's comparable quarter.

  • Other quarterly highlights include:

  • Net income of $3.7 million, up 17% over last year's comparable quarter.
  • Total medical and veterinary instrument sales of $7.6 million, up 17% over last year's comparable quarter.
  • Veterinary market sales of $26.6 million, up 23% over last year's comparable quarter.
  • Medical market sales of $6.9 million, up 8% over last year's comparable quarter.
  • Total medical and veterinary reagent disc sales of $19.3 million, up 6% over last year's comparable quarter.
  • Cash, cash equivalents and investments as of September 30, 2010 of $100.6 million, compared to $87.6 million as of September 30, 2009.

  • Quarterly Results: For the fiscal quarter ended September 30, 2010, Abaxis reported revenues of $35.3 million, as compared with revenues of $30.3 million for the comparable period last year, an increase of 17 percent.
    Revenues from instrument sales, which include chemistry analyzers, hematology instruments, coagulation analyzers and i-STAT analyzers, increased by an aggregate of $1.1 million, or 17 percent, over the same period last year.  Total medical and veterinary instrument sales were 988 units, up 7 percent over the same period last year.  Revenues from consumables, which include reagent discs, hematology reagent kits, coagulation cartridges, i-STAT cartridges and heartworm rapid tests, increased by an aggregate of $4.3 million, or 21 percent, over the same period last year.
    The company reported net income of $3.7 million for the fiscal quarter ended September 30, 2010, compared to $3.2 million for the same period last year.
    The company's effective tax rate in both three-month periods was 39 percent.
    The company reported diluted net income per share of $0.17 (calculated based on 22,691,000 shares) for the three-month period ended September 30, 2010, compared to $0.14 per share (calculated based on 22,574,000 shares) for the same period last year.

    Six-Month Results:  For the six-month period ended September 30, 2010, Abaxis reported revenues of $70.2 million, as compared with revenues of $59.9 million for the comparable period last year, an increase of 17 percent.
    Revenues from instrument sales increased by an aggregate of $2.1 million, or 17 percent, over the same period last year.
    Total medical and veterinary instrument sales were 2,013 units, up 14 percent over the same period last year.
    Revenues from consumables increased by an aggregate of $8.7 million, or 21 percent, over the same period last year.
    The company reported net income of $7.3 million, compared to $7.0 million for the same period last year.
    The company's effective tax rate in the six-month period ended September 30, 2010, was 39 percent, compared to 40 percent for the same period last year.
    The company reported diluted net income per share of $0.32 (calculated based on 22,736,000 shares) for the six-month period ended September 30, 2010, compared to $0.31 per share (calculated based on 22,492,000 shares) for the same period last year.

    Other Reported Information:  Consumables revenues for the second quarter of fiscal 2011 were $25.3 million, up 21 percent over the $21.0 million reported for the same period last year.  Total sales in the medical market for the second quarter of fiscal 2011 were $6.9 million, an increase of 8 percent compared to the same period last year.  Medical sales worldwide, excluding sales to the U.S. government, during the second quarter of fiscal 2011 were $6.0 million, an increase of 7 percent compared to the same period last year.  Total sales in the veterinary market for the second quarter of fiscal 2011 were $26.6 million, an increase of 23 percent compared to the same period last year.  Veterinary reagent disc sales for the second quarter of fiscal 2011 were $14.8 million, an increase of 8 percent compared to the same period last year.  Non-cash compensation expense recognized for share-based awards during the second quarter of fiscal 2011 was $1.1 million, compared to $1.4 million for the same period last year.

    Clint Severson, chairman and chief executive officer of Abaxis, commented, "On a year-over-year basis revenues and net income for the quarter were both up 17%, led by a 23% increase in veterinary market revenues and a 38% increase in the number of Piccolo chemistry analyzer units sold in the medical market compared to last year's second quarter.  We also achieved strong growth in consumables sales of 21% for the quarter.  We are very pleased with the traction that we are gaining across our various markets.  A strong focus on more effective sales and marketing efforts across all of our platforms has driven those gains."

    Mr. Severson continued, "We are also very pleased that our razor/razorblade model continues to deliver outstanding results; 72% of our quarterly revenues are recurring and we believe that there is still headroom to drive this percentage higher in the coming years.  In that regard, we believe that the substantial increase in the number of medical instruments placed in urgent care centers and in the internal medicine markets during the quarter will be solid contributors to our recurring revenue model.  Additionally, we are dedicated to a strong and consistent research and development process to introduce new products that effectively diagnose conditions in both the veterinary and medical markets and that provide an additional cash flow stream to the medical professionals that rely on Abaxis technology.  We also look forward to entering into the rapid testing market by taking full advantage of the lateral flow technology that we licensed.  We believe there are exciting growth opportunities ahead in the coming years."

    Conference CallAbaxis has scheduled a conference call to discuss its results at 4:15 p.m. Eastern Time on Tuesday, October 26, 2010.  Participants can dial (877) 317-6789 or (412) 317-6789 to access the conference call, or can listen via a live Internet web cast, which is available in the Investor Relations section of the company's website at http://www.abaxis.com.  A replay of the call is available by visiting http://www.abaxis.com for the next 30 days or by calling (877) 344-7529 or (412) 317-0088, access code 445369, through October 29, 2010.  This press release is also available prior to and after the call via Abaxis' website or the Securities and Exchange Commission's website at http://www.sec.gov.

    About AbaxisAbaxis develops, manufactures, markets and sells portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements.  The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients.  The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples.  The system provides test results in less than 12 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer.

    Use of Financial MeasuresTo supplement the financial statements presented in accordance with United States generally accepted accounting principles (GAAP), Abaxis uses operating income per share, a non-GAAP financial measure.  The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.  For more information on this non-GAAP financial measure, refer to the table captioned "Operating Income Per Share" included at the end of this release.  Abaxis defines operating income per share as operating income divided by the weighted average outstanding shares.  Management uses this measure in comparing Abaxis' operating results with historical performance and believes it provides meaningful and comparable information to management and investors to assist in their review of Abaxis' performance relative to prior periods and its competitors.

    This press release includes, and our conference call will include, statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"), including but not limited to statements related to Abaxis' cash position, financial resources and potential for future growth, market acceptance of new or planned product offerings, process improvements and product manufacturing quality and efficiencies in future production of our products.  Abaxis claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act.  These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," "anticipates," or words of similar import, and do not reflect historical facts.  Specific forward-looking statements contained in this press release or in Abaxis' conference call may be affected by risks and uncertainties, including, but not limited to, those related to the market acceptance of the company's products and the continuing development of its products, required United States Food and Drug Administration clearance and other government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with entering the human diagnostic market on a larger scale, risks related to the protection of the company's intellectual property or claims of infringement of intellectual property asserted by third parties, risks related to condition of the United States economy, risks involved in carrying of inventory and other risks detailed under "Risk Factors" in Abaxis' Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2010 and Abaxis' other periodic reports filed from time to time with the United States Securities and Exchange Commission.  Forward-looking statements speak only as of the date the statements were made.  Abaxis does not undertake and specifically disclaims any obligation to update any forward-looking statements.

    Financial Tables on Following PagesABAXIS, INC.Condensed Consolidated Statements of Income(in thousands, except per share data)(Unaudited)Three Months EndedSix Months EndedSeptember 30,September 30,2010200920102009Revenues

    $
    35,277

    $
    30,262

    $
    70,230

    $
    59,887Cost of revenues

    15,527

    12,411

    30,696

    24,881Gross profit

    19,750

    17,851

    39,534

    35,006Operating expenses:   Research and development

    3,296

    2,594

    6,374

    5,167   Sales and marketing

    8,408

    7,582

    17,041

    13,942   General and administrative

    2,652

    2,689

    4,776

    5,187Total operating expenses

    14,356

    12,865

    28,191

    24,296Income from operations

    5,394

    4,986

    11,343

    10,710Interest and other income (expense), net

    757

    292

    652

    806Income before income tax provision

    6,151

    5,278

    11,995

    11,516Income tax provision

    2,402

    2,081

    4,666

    4,563Net income

    $
    3,749

    $
    3,197

    $
    7,329

    $
    ,953Net income per share:  Basic net income per share

    $
    .17

    $
    .15

    $
    .33

    $
    .32  Diluted net income per share

    $
    .17

    $
    .14

    $
    .32

    $
    .31Shares used in the calculation of net income per share:  Weighted average common shares outstanding - basic

    22,317

    22,005

    22,264

    21,985  Weighted average common shares outstanding - diluted

    22,691

    22,574

    22,736

    22,492ABAXIS, INC.Condensed Consolidated Balance Sheets(Unaudited and in thousands)September 30,March 31,20102010Current assets:Cash and cash equivalents

    $
    40,650

    $
    27,857Short-term investments

    31,293

    32,343Receivables, net

    24,878

    23,714Inventories

    17,950

    19,067Prepaid expenses and other current assets

    2,307

    1,588Net deferred tax assets, current

    3,297

    3,773 Total current assets

    120,375

    108,342Long-term investments

    28,683

    36,319Property and equipment, net

    15,772

    15,544Intangible assets, net

    4,313

    4,600Net deferred tax assets, non-current

    2,935

    2,935Other assets

    103

    76 Total assets

    $
    72,181

    $
    7,816Current liabilities: Accounts payable

    $
    5,483

    $
    9,404 Accrued payroll and related expenses

    5,754

    5,615 Accrued taxes

    267

    400 Other accrued liabilities

    1,217

    1,256 Deferred revenue

    975

    1,157 Warranty reserve

    798

    1,183  Total current liabilities

    14,494

    19,015Non-current liabilities: Deferred rent

    328

    163 Deferred revenue

    1,674

    1,359 Warranty reserve

    53

    160  Total non-current liabilities

    2,055

    1,682Shareholders' equity:  Common stock

    126,234

    125,050  Retained earnings

    29,398

    22,069   Total shareholders' equity

    155,632

    147,119   Total liabilities and shareholders' equity

    $
    72,181

    $
    7,816Operating Income Per Share(In thousands, except per share data)Three Months EndedSix Months EndedSeptember 30,September 30,2010200920102009Shares used in the calculation of operating income per share:  Weighted average common shares outstanding - basic

    22,317

    22,005

    22,264

    21,985  Weighted average common shares outstanding - diluted

    22,691

    22,574

    22,736

    22,492Operating income per share - basic

    $
    .24

    $
    .23

    $
    .51

    $
    .49Operating income per share - diluted

    $
    .24

    $
    .22

    $
    .50

    $
    .48Revenues by Geographic Region(In thousands)Three Months EndedSix Months EndedSeptember 30,September 30,2010200920102009North America

    $
    29,528

    $
    24,774

    $
    57,317

    $
    48,885International

    5,749

    5,488

    12,913

    11,002Total revenues

    $
    35,277

    $
    30,262

    $
    70,230

    $
    59,887Revenues by Customer Group(In thousands)Three Months EndedSix Months EndedSeptember 30,September 30,2010200920102009Medical Market

    $
    ,857

    $
    ,345

    $
    3,295

    $
    2,108Veterinary Market

    26,649

    21,684

    53,467

    43,507Other

    1,771

    2,233

    3,468

    4,272Total revenues

    $
    35,277

    $
    30,262

    $
    70,230

    $
    59,887
    '/>"/>

    SOURCE Abaxis, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Abaxis to Report Second Quarter Fiscal 2011 Financial Results Tuesday, October 26, 2010
    2. Abaxis, Inc. to Present at Sidoti & Companys Ninth Annual West Coast Institutional Investor Forum
    3. Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010
    4. Abaxis, Inc. to Present at the 21st Annual Piper Jaffray Health Care Conference
    5. Abaxis, Inc. to Present at the Sidoti & Company Second Annual New York Institutional Investor Forum
    6. Abaxis to Report Second Quarter Fiscal 2010 Financial Results Tuesday, October 27, 2009
    7. ABAXIS Announces Launch of the First Fully Automated Canine Wellness Profile That Includes a Canine Heartworm Antigen Test
    8. Intercell Reports Positive Results From Its Phase II Pseudomonas Aeruginosa Investigational Vaccine Study for Certain Hospital-Acquired Infections
    9. Assured Pharmacy Reports Same Store Sales for the Month of September 2010
    10. Danaher Reports Record Third Quarter 2010 Results
    11. Quest Diagnostics Reports Third Quarter 2010 Financial Results; Updates Guidance for 2010
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
    (Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
    (Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of ... Farma Brasil as the company,s second affiliate in Latin America . ... ... Manager of Astellas Farma Colombia ... ...
    Breaking Medicine Technology:
    (Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
    (Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
    (Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
    (Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
    (Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
    Breaking Medicine News(10 mins):